Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Oct 28, 2022--
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, today announced that fourth quarter and fiscal year 2022 financial results will be released before the market opens on Wednesday, November 9 th.
Management will host a live webcast and conference call at 7:00 a.m. CT (8:00 a.m. ET) on Wednesday, November 9 th, to discuss the fourth quarter fiscal 2022 financial results and accomplishments and host a question-and-answer session. To access the webcast, navigate to upcoming events under the ‘events and presentations’ tab within the investor relations portion of the Company’s website at https://surmodics.gcs-web.com/events-and-presentations. To listen to the live teleconference, dial 888-428-7458 (international callers may dial 862-298-0702) and provide access ID: 13733806.
An audio replay of the conference call will be available beginning at 11:00 a.m. CT on Wednesday, November 9 th, until 11:00 a.m. CT on Wednesday, November 23 rd, and can be accessed by dialing 877-660-6853 (international callers may dial 201-612-7415) and entering access ID: 13733806. In addition, the webcast and transcript will be archived on the Company’s website following the call.
About Surmodics, Inc.
Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221028005070/en/
CONTACT: Surmodics Investor Inquiries:
Jack Powell, Investor Relations,ir@surmodics.com
KEYWORD: MINNESOTA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH MANUFACTURING GENERAL HEALTH OTHER MANUFACTURING BIOTECHNOLOGY
SOURCE: Surmodics, Inc.
Copyright Business Wire 2022.
